ASCO 2014 – Immuno-Oncology

Pidilizumab in Relapsed Metastatic Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab and Erlotinib in EGFR-Mutation Positive Treatment-Resistant Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab in Chemotherapy-Naïve Advanced NSCLC

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Blinatumomab in Relapsed/Refractory Acute Lymphoblastic Leukemia

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Adoptive T-Cell Therapy for Cervical Cancer

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Pembrolizumab (MK-3745) in Metastatic Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Concurrent Treatment of Advanced Melanoma with Ipilimumab and Nivolumab

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Ipilimumab for Initial Treatment of Metastatic Uveal Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Nivolumab Combined with Ipilimumab in Metastatic Renal Cell Carcinoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Adjuvant Ipilimumab for Patients with High-Risk Melanoma

ASCO 2014 – Immuno-Oncology, ASCO

Conference Correspondent

Page 1 of 3

1
2
3